JP2006517940A - 神経障害性疼痛におけるｒ−１０−ヒドロキシ−１０，１１−ジヒドロ−カルバマゼピンの使用 - Google Patents
神経障害性疼痛におけるｒ−１０−ヒドロキシ−１０，１１−ジヒドロ−カルバマゼピンの使用 Download PDFInfo
- Publication number
- JP2006517940A JP2006517940A JP2006501857A JP2006501857A JP2006517940A JP 2006517940 A JP2006517940 A JP 2006517940A JP 2006501857 A JP2006501857 A JP 2006501857A JP 2006501857 A JP2006501857 A JP 2006501857A JP 2006517940 A JP2006517940 A JP 2006517940A
- Authority
- JP
- Japan
- Prior art keywords
- enantiomer
- neuropathic pain
- formula
- mixture
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 20
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 10
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 208000004454 Hyperalgesia Diseases 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 7
- 208000035154 Hyperesthesia Diseases 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical class C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
- 229930007927 cymene Natural products 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000009132 Catalepsy Diseases 0.000 description 2
- GCOFJKCZHSUXML-UHFFFAOYSA-N O=C1CC2=C(N(C3=C1C=CC=C3)C(=O)N)C=CC=C2.N2C=CC=C(C=C2)C(=O)N Chemical compound O=C1CC2=C(N(C3=C1C=CC=C3)C(=O)N)C=CC=C2.N2C=CC=C(C=C2)C(=O)N GCOFJKCZHSUXML-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010047853 Waxy flexibility Diseases 0.000 description 2
- 230000003070 anti-hyperalgesia Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- CZVXMPYMWAKWEV-UIOOFZCWSA-N n-[(1s,2s)-2-amino-1,2-diphenylethyl]-5-(dimethylamino)naphthalene-1-sulfonamide Chemical compound C1([C@H](N)[C@@H](NS(=O)(=O)C2=C3C=CC=C(C3=CC=C2)N(C)C)C=2C=CC=CC=2)=CC=CC=C1 CZVXMPYMWAKWEV-UIOOFZCWSA-N 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 2
- 229940061414 trileptal Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LAXRNWSASWOFOT-UHFFFAOYSA-J (cymene)ruthenium dichloride dimer Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Ru+2].[Ru+2].CC(C)C1=CC=C(C)C=C1.CC(C)C1=CC=C(C)C=C1 LAXRNWSASWOFOT-UHFFFAOYSA-J 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- CZVXMPYMWAKWEV-UHFFFAOYSA-N CN(C)C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)NC(C(N)C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CN(C)C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)NC(C(N)C1=CC=CC=C1)C1=CC=CC=C1 CZVXMPYMWAKWEV-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- PONXTPCRRASWKW-KBPBESRZSA-N diphenylethylenediamine Chemical compound C1([C@H](N)[C@@H](N)C=2C=CC=CC=2)=CC=CC=C1 PONXTPCRRASWKW-KBPBESRZSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 235000008790 seltzer Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0303615.9A GB0303615D0 (en) | 2003-02-17 | 2003-02-17 | Use of organic compounds |
| PCT/EP2004/001451 WO2004071513A1 (en) | 2003-02-17 | 2004-02-16 | Use of r-10-hydroxy-10, 11-dihydro-carbamazepine in neuropathic pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517940A true JP2006517940A (ja) | 2006-08-03 |
| JP2006517940A5 JP2006517940A5 (https=) | 2007-04-12 |
Family
ID=9953162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006501857A Pending JP2006517940A (ja) | 2003-02-17 | 2004-02-16 | 神経障害性疼痛におけるｒ−１０−ヒドロキシ−１０，１１−ジヒドロ−カルバマゼピンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20060166967A1 (https=) |
| EP (1) | EP1596865A1 (https=) |
| JP (1) | JP2006517940A (https=) |
| CN (1) | CN1750826A (https=) |
| AU (1) | AU2004212327A1 (https=) |
| BR (1) | BRPI0407529A (https=) |
| CA (1) | CA2516265A1 (https=) |
| GB (1) | GB0303615D0 (https=) |
| MX (1) | MXPA05008711A (https=) |
| PL (1) | PL376755A1 (https=) |
| WO (1) | WO2004071513A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1879590A1 (en) * | 2005-05-06 | 2008-01-23 | Portela & Ca., S.A. | Eslicarbazepine acetate and methods of use |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0517740D0 (en) * | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| WO2011017319A1 (en) * | 2009-08-03 | 2011-02-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating disorders associated with protein polymerization |
| US8809617B2 (en) | 2009-11-05 | 2014-08-19 | The University of Pittsburgh—Of the Commonwealth System of Higher Education | Automated high-content live animal drug screening using C. elegans |
| US9072772B2 (en) | 2009-11-05 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating disorders associated with protein aggregation |
| CN116063231A (zh) * | 2021-10-29 | 2023-05-05 | 上药康丽（常州）药业有限公司 | 一种s-利卡西平的回收方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0435826A1 (de) * | 1989-12-27 | 1991-07-03 | Ciba-Geigy Ag | Intravenöse Lösungen für Status Epilepticus |
| WO2002096881A1 (en) * | 2001-05-25 | 2002-12-05 | Portela & Ca Sa | Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-0x0-5h-dibenz/b,f/azepine-5-carboxamide |
| JP2006504710A (ja) * | 2002-10-07 | 2006-02-09 | ノバルティス アクチエンゲゼルシャフト | １０，１１−ジヒドロ−１０−ヒドロキシ−５Ｈ−ジベンズ［ｂ，ｆ］アゼピン−５−カルボキサミドの両エナンチオマーのエナンチオ選択的製造方法およびその新規結晶形 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH505101A (de) * | 1969-03-31 | 1971-03-31 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| US5534495A (en) * | 1993-05-25 | 1996-07-09 | Advanced Peptides And Biotechnology Sciences | Treatment of non-HIV neuropathic pain syndromes |
| US5688830A (en) * | 1996-01-25 | 1997-11-18 | Syntex (U.S.A.) Inc. | Treatment of neuropathic pain |
| KR20050044396A (ko) * | 2001-11-12 | 2005-05-12 | 노파르티스 아게 | 정동 및 주의력 장애 및 신경병성 통증 치료용 의약제조에 사용하기 위한 모노히드록시카르바마제핀 |
| WO2004014391A1 (en) * | 2002-08-06 | 2004-02-19 | Novartis Ag | Use of carboxamides for the treatment of tinnitus |
-
2003
- 2003-02-17 GB GBGB0303615.9A patent/GB0303615D0/en not_active Ceased
-
2004
- 2004-02-16 CN CNA2004800044023A patent/CN1750826A/zh active Pending
- 2004-02-16 MX MXPA05008711A patent/MXPA05008711A/es not_active Application Discontinuation
- 2004-02-16 EP EP04711348A patent/EP1596865A1/en not_active Withdrawn
- 2004-02-16 PL PL376755A patent/PL376755A1/pl not_active Application Discontinuation
- 2004-02-16 JP JP2006501857A patent/JP2006517940A/ja active Pending
- 2004-02-16 AU AU2004212327A patent/AU2004212327A1/en not_active Abandoned
- 2004-02-16 CA CA002516265A patent/CA2516265A1/en not_active Abandoned
- 2004-02-16 BR BRPI0407529-3A patent/BRPI0407529A/pt not_active IP Right Cessation
- 2004-02-16 WO PCT/EP2004/001451 patent/WO2004071513A1/en not_active Ceased
-
2005
- 2005-02-16 US US10/545,410 patent/US20060166967A1/en not_active Abandoned
-
2008
- 2008-10-30 US US12/261,655 patent/US20090054404A1/en not_active Abandoned
-
2009
- 2009-12-08 US US12/633,231 patent/US20100120746A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0435826A1 (de) * | 1989-12-27 | 1991-07-03 | Ciba-Geigy Ag | Intravenöse Lösungen für Status Epilepticus |
| WO2002096881A1 (en) * | 2001-05-25 | 2002-12-05 | Portela & Ca Sa | Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-0x0-5h-dibenz/b,f/azepine-5-carboxamide |
| JP2006504710A (ja) * | 2002-10-07 | 2006-02-09 | ノバルティス アクチエンゲゼルシャフト | １０，１１−ジヒドロ−１０−ヒドロキシ−５Ｈ−ジベンズ［ｂ，ｆ］アゼピン−５−カルボキサミドの両エナンチオマーのエナンチオ選択的製造方法およびその新規結晶形 |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05008711A (es) | 2005-10-05 |
| EP1596865A1 (en) | 2005-11-23 |
| US20090054404A1 (en) | 2009-02-26 |
| WO2004071513A1 (en) | 2004-08-26 |
| PL376755A1 (pl) | 2006-01-09 |
| GB0303615D0 (en) | 2003-03-19 |
| US20060166967A1 (en) | 2006-07-27 |
| BRPI0407529A (pt) | 2006-02-14 |
| CN1750826A (zh) | 2006-03-22 |
| AU2004212327A1 (en) | 2004-08-26 |
| CA2516265A1 (en) | 2004-08-26 |
| US20100120746A1 (en) | 2010-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100120746A1 (en) | Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain | |
| CN101378741A (zh) | 治疗神经性疼痛的方法 | |
| CN102652135A (zh) | 脂肪酸酰胺水解酶的含氮杂环抑制剂 | |
| US20100063029A1 (en) | Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders | |
| AU2004226827B2 (en) | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders | |
| US6187807B1 (en) | Methods of use and compositions of (S) (-)-amisulpride | |
| CN102325768A (zh) | 治疗疼痛和其他疾病的化合物和方法 | |
| AU2017216288B2 (en) | Novel combinatorial therapies of neurological disorders | |
| CN113582911B (zh) | 多靶点多奈哌齐-异羟肟酸型化合物及其制备方法和应用 | |
| EA033769B1 (ru) | ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ | |
| US7465723B2 (en) | Use of carboxamides for the treatment of tinnitus | |
| FI61182C (fi) | Foerfarande foer framstaellning av farmaceutiskt aktiva butylaminderivat | |
| CN100356923C (zh) | S－10－羟基－10,11－二氢－卡马西平在制备药物组合物中的用途 | |
| AU2009292498A1 (en) | Novel pharmaceutical composition for treatment of nociceptive pain | |
| AU2007222112A1 (en) | Alpha-2-delta ligands for non-restorative sleep | |
| AU2007251901A1 (en) | Use of S-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders | |
| AU2008201166A1 (en) | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070221 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100810 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101110 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101117 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110315 |